EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M Landrum, Lars C Hanker, Ashley Stuckey und 20 weitere

New England Journal of Medicine · 08.06.2023 · 388 (23) · 2145-2158

DOI: 10.1056/nejmoa2216334 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.06.2023. Verfasst von Mansoor R Mirza und 31 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Uni…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 882-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsNeoplasm Recurrence, LocalFemaleHumansAntibodies, Monoclonal, HumanizedCarboplatinDNA Mismatch RepairDouble-Blind MethodImmune Checkpoint InhibitorsMicrosatellite InstabilityPaclitaxel

Substanzen

Antibodies, Monoclonal, HumanizedCarboplatindostarlimabImmune Checkpoint InhibitorsPaclitaxel

Autor:innen und Institutionen

  • From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, Un…

Förderung

  • GlaxoSmithKline

Zitieren

APA

Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Hanker, L. C., Stuckey, A., Boere, I., Gold, M. A., Auranen, A., Pothuri, B., Cibula, D., McCourt, C., Raspagliesi, F., …, & RUBY Investigators (2023). Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine, 388(23), 2145-2158. https://doi.org/10.1056/nejmoa2216334

Vancouver

Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine. 2023;388(23):2145-2158. doi:10.1056/nejmoa2216334

BibTeX
@article{Mirza2023,
  author = {Mirza, Mansoor R and Chase, Dana M and Slomovitz, Brian M and dePont Christensen, René and Novák, Zoltán and Black, Destin and Gilbert, Lucy and Sharma, Sudarshan and Valabrega, Giorgio and Landrum, Lisa M and Hanker, Lars C and Stuckey, Ashley and Boere, Ingrid and Gold, Michael A and Auranen, Annika and Pothuri, Bhavana and Cibula, David and McCourt, Carolyn and Raspagliesi, Francesco and Shahin, Mark S and Gill, Sarah E and Monk, Bradley J and Buscema, Joseph and Herzog, Thomas J and Copeland, Larry J and Tian, Min and He, Zangdong and Stevens, Shadi and Zografos, Eleftherios and Coleman, Robert L and Powell, Matthew A and RUBY Investigators, RUBY Investigators},
  title = {Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {23},
  pages = {2145--2158},
  doi = {10.1056/nejmoa2216334}
}
Kostenlos starten →